SecurityHALO / Halozyme Therapeutics, Inc. (40637H109)
Latest Market Date2018-08-17
Short Volume23,701
Market Volume 966,200
Short Percent 2%

Short Interest and Volume

HALO / Halozyme Therapeutics, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.

Short Volume
Total number of short shares traded on the major US markets each day
Short Percent
Total number of short shares traded divided by the total shares traded each day
Short Interest
Total number of open short positions of a security, divided by the total float (not shown)
Short Squeeze
When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.

Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.

Market Date Total Volume Short Volume Short Percent
2018-08-17 966,200 23,701 2.45
2018-08-16 1,424,600 42,358 2.97
2018-08-15 931,600 39,615 4.25
2018-08-14 2,201,800 59,209 2.69
2018-08-13 1,665,000 50,260 3.02
2018-08-10 2,503,800 166,640 6.66
2018-08-09 2,540,000 91,281 3.59
2018-08-08 2,483,200 238,857 9.62
2018-08-07 1,348,800 73,929 5.48
2018-08-06 1,340,200 172,032 12.84
HALO: Halozyme Therapeutics Analysis and Research Report

2018-02-13 - Asif

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. The company's proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. The company exploit its technology and expertise using a two pillar strategy that the company believe enables it to manage risk and cost by: (1) developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing its technology to biopharmaceutical companies to collaboratively develop products that combine its technology with the collaborators’ proprietary compounds. The majority of its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company's proprietary development pipeline con...

Related Articles

RNVA: Rennova Health Analysis and Research Report

4h - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

Silicon Investor Message Boards

This table lists all message boards related to HALO / Halozyme Therapeutics, Inc. on message board site Silicon Investor.

BS Bernanke (Ben Shalom Bernanke), 14th Fed Chairman BS Bernanke (Ben Shalom Bernanke), 14th Fed Chairman BS Bernanke (Ben Shalom Bernanke), 14th Fed Chairman HALO Technologies Holdings, Inc HALO Technologies Holdings, Inc HALO Technologies Holdings, Inc
Modified Athalon for Overclocking? Modified Athalon for Overclocking? Modified Athalon for Overclocking? Cephalon (CEPH) Coiled u0026 Ready Cephalon (CEPH) Coiled u0026 Ready Cephalon (CEPH) Coiled u0026 Ready
CUSIP: 40637H109